Professional paper
TREATMENT OF MULTIPLE SCLEROSIS WITH OCRELIZUMAB – A RETROSPECTIVE 1.5-YEAR ANALYSIS AT DEPARTMENT OF NEUROLOGY, SESTRE MILOSRDNICE UNIVERSITY HOSPITAL CENTRE IN ZAGREB
NEVENA GRBIĆ
orcid.org/0000-0003-1537-3734
; Sestre milosrdnice University Hospital Centre, Department of Neurology, Referral Centre for Neuroimmunology and Neurogenetics of the Ministry of Health, Zagreb, Croatia
MILJENKA-JELENA JURAŠIĆ
; Sestre milosrdnice University Hospital Centre, Department of Neurology, Referral Centre for Neuroimmunology and Neurogenetics of the Ministry of Health, Zagreb, Croatia
LUCIJA ZADRO MATOVINA
; Sestre milosrdnice University Hospital Centre, Department of Neurology, Referral Centre for Neuroimmunology and Neurogenetics of the Ministry of Health, Zagreb, Croatia
IRIS ZAVORERO
orcid.org/0000-0001-9358-1665
; Sestre milosrdnice University Hospital Centre, Department of Neurology, Referral Centre for Neuroimmunology and Neurogenetics of the Ministry of Health;Faculty of Kinesiology, University of Zagreb, Zagreb, Croatia
IVANA VINSKI
; Sestre milosrdnice University Hospital Centre, Department of Neurology, Referral Centre for Neuroimmunology and Neurogenetics of the Ministry of Health, Zagreb, Croatia
VANJA BAŠIĆ KES
; Sestre milosrdnice University Hospital Centre, Department of Neurology, Referral Centre for Neuroimmunology and Neurogenetics of the Ministry of Health; School of Dental Medicine, University of Zagreb; School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Abstract
Considering importance of T lymphocytes in the pathogenesis of multiple sclerosis, the importance of B lymphocytes in the pathogenesis of the disease is increasingly revealed. Ocrelizumab (Ocrevus®, Roche, Germany) is a monoclonal antibody that targets B cells expressing CD20 antigen. Numerous studies have demonstrated the effi cacy of ocrelizumab in the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Previous clinical trials have shown that ocrelizumab administration suppresses relapses, disease progression and subclinical disease activity as determined by the method of magnetic resonance imaging. We retrospectively analyzed patients at the Department of Neurology, Sestre milosrdnice University Hospital Centre. Ocrelizumab was administered to 36 patients with RRMS and 13 patients with PPMS. The aim was to present the population of patients administered the drug, their side effects and clinical outcome after administration of the drug, comparing the above data with current knowledge on the drug. In our RRMS group analysis, 47% of patients were administered second treatment cycle and 8% were administered third cycle; 94% of these patients showed no clinical progression of the disease. In the groups of RRMS and PPMS patients, adverse events were recorded in 11% and 23% of patients, respectively. The most common side effects were response to infusion and decrease in lymphocyte count (still at the border of the lower reference value). The analysis of our patients confi rmed previous fi ndings of clinical studies. The drug has been proven to be safe to administer with a low incidence of side effects. Nevertheless, more patients are needed for further and detailed analysis, motivating us for further monitoring and publication of a new analysis in the future.
Keywords
multiple sclerosis; ocrelizumab; treatment; experience
Hrčak ID:
245742
URI
Publication date:
6.11.2020.
Visits: 2.921 *